Business context and reporting period
Entity mismatch: The supplied filing is Frequency Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2022, filed November 8, 2022. It is not a Korro Bio, Inc. filing. The company is a clinical-stage regenerative medicine business developing hearing-loss candidates FX-322 and FX-345 and a preclinical remyelination program for multiple sclerosis (MS).
Financial performance and position
Amounts below are in millions of dollars unless noted. The company had no product sales and recognized no revenue in the third quarter or first nine months of 2022. It reported net losses of $19.5 million for the quarter and $64.2 million for the nine months ended September 30.
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $14.1 |
| Research and development expense | $11.7 | $15.7 | $38.8 | $48.2 |
| General and administrative expense | $8.6 | $9.3 | $26.0 | $28.6 |
| Operating loss | $(20.3) | $(25.0) | $(64.8) | $(62.7) |
| Net loss | $(19.5) | $(25.2) | $(64.2) | $(63.2) |
| Basic and diluted loss per share | $(0.55) | $(0.73) | $(1.83) | $(1.84) |
Cash, cash equivalents and marketable securities totaled $99.3 million at September 30, 2022, down from $142.4 million at December 31, 2021. Nine-month operating cash use was $42.6 million, compared with $58.2 million in 2021; investing activities provided $6.6 million, while financing activities provided $0.3 million. Total assets were $136.0 million and stockholders’ equity was $82.0 million at quarter-end. Term-loan principal totaled $15.0 million: $8.3 million current and $6.7 million long-term. The loan rate was 7.75% at September 30; interest-only payments were scheduled through November 2022, followed by principal and interest installments through May 2024. No operating margin is meaningful given the absence of revenue.
Material changes versus the prior comparable period
- Quarterly net loss improved by $5.6 million year over year, mainly as operating expenses fell $4.7 million. Nine-month net loss increased by $1.0 million despite $11.9 million lower operating expenses, chiefly because 2021 included $14.1 million of Astellas collaboration revenue from recognition of the previously paid upfront fee.
- Research and development expense declined 25% for the quarter and 20% for the nine-month period; G&A expense declined 8% and 9%, respectively. The filing attributes much of the reduction to employee attrition and lower professional-service and facility costs.
- Cash and cash equivalents declined to $43.8 million from $79.6 million at year-end 2021; short-term marketable securities were $55.5 million, with no long-term securities reported at quarter-end.
- The company reduced its workforce by approximately 30% in April 2022. It reported approximately $1.2 million of total termination costs, primarily severance and related expenses.
Outlook, risks and unusual items
- Management estimated existing cash, cash equivalents and marketable securities would fund operating expenses and capital spending into 2024, while warning that assumptions could prove wrong. The filing also states resources were expected to fund planned operations for at least 12 months from when the financial statements were available to issue.
- FX-322-208 completed enrollment at 142 subjects in October 2022; management planned to report data in Q1 2023. The FDA had agreed speech perception was an acceptable primary efficacy endpoint. FX-322 had previously produced mixed clinical evidence: the Phase 2a trial did not show hearing improvement versus placebo, while selected earlier studies reported signals and generally favorable tolerability.
- Management planned to start an FX-345 Phase 1b trial in Q4 2022, with results expected in the second half of 2023. It targeted an IND submission for its MS remyelination program in the second half of 2023. These are forward-looking plans, not assured outcomes.
- In August, the board repriced eligible underwater options to $2.14 per share, resulting in $2.5 million of incremental stock-based compensation, of which $1.5 million was expensed in Q3. Stock-based compensation totaled $5.6 million for the quarter.
- A sublease of Lexington office space generated $0.6 million of income in Q3; expected future sublease income was $4.3 million as of September 30, 2022.
- The company disclosed securities class-action, shareholder, and derivative litigation. It said it could not estimate possible losses and recorded no accruals for these matters. Other key risks include clinical and regulatory failure, dependence on FX-322, need for future financing, reliance on third-party manufacturers and trial organizations, and the possibility of disruption from COVID-19 or geopolitical and economic conditions.
- The company had an ATM equity program with capacity for up to $125 million in gross sales proceeds; it sold shares for approximately $0.05 million net during the first nine months of 2022 and none in Q3. Further equity financing could dilute shareholders.
Important facts for investors to verify
- Confirm the filing identity: this is Frequency Therapeutics, Inc. (Nasdaq: FREQ), not Korro Bio, Inc.
- Track final FX-322-208 results against the Q1 2023 timing disclosed, and assess the trial’s endpoint and findings.
- Check whether FX-345 and the MS program met the stated clinical-development timelines.
- Reassess cash burn, available liquidity, debt repayment terms and whether the stated runway remains achievable.
- Monitor the status and potential financial impact of the disclosed litigation, and any subsequent financing or dilution.